DZ2729A1 - Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant. - Google Patents

Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant.

Info

Publication number: DZ2729A1
Authority: DZ; Algeria
Prior art keywords: nhe; preparation; pharmaceutical compositions; compositions containing; new inhibitors
Prior art date: 1998-02-27

Application number

DZ990032A

Other languages

English (en)

Inventor

Ernest S Hamanaka

Guzman Perez Angel

Roger B Ruggeri

Ronald T Wester

Christian J Mularski

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-27

Filing date

1999-02-24

Publication date

2005-03-01

1999-02-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-03-01 Application granted granted Critical

2005-03-01 Publication of DZ2729A1 publication Critical patent/DZ2729A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Surgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)

DZ990032A 1998-02-27 1999-02-24 Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant. DZ2729A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US7636298P	1998-02-27	1998-02-27

Publications (1)

Publication Number	Publication Date
DZ2729A1 true DZ2729A1 (fr)	2005-03-01

Family

ID=22131525

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990032A DZ2729A1 (fr)	1998-02-27	1999-02-24	Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant.

Country Status (39)

Country	Link
US (2)	US6492401B1 (fr)
EP (2)	EP1454902A1 (fr)
JP (2)	JP2002504546A (fr)
KR (4)	KR100449600B1 (fr)
CN (1)	CN1289326A (fr)
AP (1)	AP9901478A0 (fr)
AR (1)	AR015526A1 (fr)
AT (1)	ATE286034T1 (fr)
AU (1)	AU739403B2 (fr)
BG (1)	BG104803A (fr)
BR (1)	BR9908332A (fr)
CA (1)	CA2321642A1 (fr)
CO (1)	CO4980897A1 (fr)
DE (1)	DE69922930T2 (fr)
DK (1)	DK1056729T3 (fr)
DZ (1)	DZ2729A1 (fr)
EA (1)	EA003603B1 (fr)
ES (1)	ES2237080T3 (fr)
GT (1)	GT199900022A (fr)
HR (2)	HRP20000550A2 (fr)
HU (1)	HUP0204418A3 (fr)
ID (1)	ID25505A (fr)
IL (1)	IL136588A0 (fr)
IS (1)	IS5548A (fr)
NO (1)	NO20004192L (fr)
NZ (1)	NZ504769A (fr)
OA (1)	OA11450A (fr)
PA (1)	PA8468401A1 (fr)
PE (1)	PE20000334A1 (fr)
PL (1)	PL342444A1 (fr)
PT (1)	PT1056729E (fr)
SI (1)	SI1056729T1 (fr)
SK (1)	SK12342000A3 (fr)
TN (1)	TNSN99028A1 (fr)
TR (1)	TR200002480T2 (fr)
TW (1)	TWI226329B (fr)
WO (1)	WO1999043663A1 (fr)
YU (1)	YU46200A (fr)
ZA (1)	ZA991578B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100449600B1 (ko) *	1998-02-27	2004-09-21	화이자 프로덕츠 인크.	허혈 치료용 ｎ-[(치환된 5원 디아자 이불포화 고리)카르보닐] 구아니딘 유도체
FR2795726A1 (fr) *	1999-06-30	2001-01-05	Aventis Cropscience Sa	Nouveaux pyrazoles fongicides
US6441176B1 (en)	1999-10-29	2002-08-27	Pfizer Inc.	Method for preparing sodium-hydrogen exchanger type 1 inhibitor
UA72002C2 (en) *	1999-10-29	2005-01-17	Pfizer Prod Inc	Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es)	2000-01-21	2003-12-11	Inc Agouron Pharmaceuticals	Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6570013B2 (en)	2000-02-16	2003-05-27	Pfizer Inc	Salts of zopolrestat
US6555569B2 (en) *	2000-03-07	2003-04-29	Pfizer Inc.	Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CA2398446A1 (fr)	2000-04-18	2001-10-25	Agouron Pharmaceuticals, Inc.	Pyrazoles permettant d'inhiber des proteines kinases
UA73348C2 (en) *	2000-04-28	2005-07-15	Pfizer Prod Inc	Sodium-hydrogen exchanger inhibitor of the type 1 (nhe-1)
US6852733B2 (en) *	2000-04-28	2005-02-08	Pfizer Inc.	Sodium-hydrogen exchanger type 1 inhibitor
IL144507A0 (en) *	2000-07-31	2002-05-23	Pfizer Prod Inc	Use of glycogen phosphorylase inhibitors to inhibit tumor growth
AU2002210839A1 (en)	2000-11-28	2002-06-11	Pfizer Products Inc.	Preparation of sodium-hydrogen exchanger type-1 inhibitors
US6423705B1 (en)	2001-01-25	2002-07-23	Pfizer Inc.	Combination therapy
IL147696A0 (en) *	2001-01-25	2002-08-14	Pfizer Prod Inc	Combination therapy
CA2436539A1 (fr) *	2001-01-31	2002-08-08	Pfizer Products Inc.	Ethanolats d'inhibiteur de type 1 d'echangeur sodium-hydrogene
WO2002098429A1 (fr) *	2001-06-07	2002-12-12	Pfizer Products Inc.	Formes salines du zopolrestat, a savoir ethanolamine, diethanolamine ou triethanolamine
AU2002352148A1 (en) *	2001-06-29	2003-03-03	Abbott Gmnh & Co. Kg	Bis-aryl thiazole derivatives
WO2003039528A1 (fr) *	2001-11-02	2003-05-15	Aventis Pharmaceuticals Inc.	Composition pharmaceutique comprenant un agoniste d'adenosine a1/a2 et un inhibiteur d'echangeur sodium-hydrogene
CA2469305A1 (fr)	2001-12-19	2003-06-26	Frank Robert Busch	Methodes de preparation d'inhibiteurs de type 1 d'echangeurs de sodium-hydrogene
WO2003064409A1 (fr) *	2002-01-30	2003-08-07	Pfizer Products Inc.	Compositions pharmaceutiques de zoniporide mesylate et procedes d'amelioration de la solubilite du zoniporide
BR0309707A (pt) *	2002-05-02	2005-02-09	Pfizer Prod Inc	Tratamento de diabetes e complicações diabéticas com inibidores nhe-1
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
FR2840302B1 (fr) *	2002-06-03	2004-07-16	Aventis Pharma Sa	Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842524B1 (fr) *	2002-07-16	2005-04-22	Aventis Pharma Sa	Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
FR2842525B1 (fr) *	2002-07-16	2005-05-13	Aventis Pharma Sa	Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842526B1 (fr) *	2002-07-16	2007-07-13	Aventis Pharma Sa	Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
ATE440827T1 (de)	2002-12-04	2009-09-15	Ore Pharmaceuticals Inc	Melanocortin-rezeptormodulatoren
CN100436445C (zh) *	2003-02-07	2008-11-26	第一制药株式会社	吡唑衍生物
US7576121B2 (en)	2003-11-12	2009-08-18	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en)	2003-11-12	2008-01-08	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
ES2524916T3 (es)	2003-11-12	2014-12-15	Sino-Med International Alliance, Inc.	Compuestos heterocíclicos de ácido borónico
TW200526641A (en) *	2003-12-26	2005-08-16	Daiichi Seiyaku Co	Amidopyrazole derivatives
WO2005079803A1 (fr) *	2004-02-13	2005-09-01	Pfizer Products, Inc.	Composes pour traitement des maladies cardio-vasculaires
WO2006017292A1 (fr)	2004-07-12	2006-02-16	Phenomix Corporation	Composes cyano contraints
US7226942B2 (en)	2004-11-15	2007-06-05	Bristol-Myers Squibb Company	2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en)	2004-11-15	2008-04-29	Bristol-Myers Squibb Company	2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en)	2004-11-15	2007-05-08	Bristol-Myers Squibb Company	2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (fr)	2004-11-15	2006-05-26	Bristol-Myers Squibb Company	Derives de 2-aminonaphtalene et inhibiteurs de la glycogene phosphorylase associes
ES2387682T3 (es) *	2005-01-10	2012-09-28	Debiopharm S.A.	Utilización de un undecapéptido cíclico para la preparación de un medicamento administrable durante situaciones isquémicas miocárdicas
WO2006113261A2 (fr)	2005-04-14	2006-10-26	Bristol-Myers Squibb Company	Inhibiteurs de la 11-beta hydroxysteroide deshydrogenase de type i
US7825139B2 (en)	2005-05-25	2010-11-02	Forest Laboratories Holdings Limited (BM)	Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2008005910A2 (fr)	2006-07-06	2008-01-10	Bristol-Myers Squibb Company	Inhibiteurs de type i de la 11-bêta hydroxystéroïde déshydrogénase pyridone/hydroxypyridine
US7727978B2 (en)	2006-08-24	2010-06-01	Bristol-Myers Squibb Company	Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8546394B2 (en)	2007-04-17	2013-10-01	Bristol-Myers Squibb Company	Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
WO2009018065A2 (fr)	2007-07-27	2009-02-05	Bristol-Myers Squibb Company	Nouveaux activateurs de glucokinase et procédés pour les utiliser
PT2294066E (pt) *	2008-04-28	2014-11-21	Janssen Pharmaceutica Nv	Benzoimidazoles como inibidores da prolil-hidroxilase
US10517839B2 (en)	2008-06-09	2019-12-31	Cornell University	Mast cell inhibition in diseases of the retina and vitreous
JP5621148B2 (ja) *	2008-11-21	2014-11-05	ラクオリア創薬株式会社	５−ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール−３−カルボキサミド誘導体
WO2010094090A2 (fr) *	2009-02-18	2010-08-26	Katholleke Universiteit Leuven	Synucléinopathies
WO2011130459A1 (fr)	2010-04-14	2011-10-20	Bristol-Myers Squibb Company	Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs
CN102408385B (zh) *	2011-06-20	2014-06-18	雅本化学股份有限公司	一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) *	2011-07-27	2014-05-07	雅本化学股份有限公司	2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
WO2013041602A1 (fr)	2011-09-23	2013-03-28	Bayer Intellectual Property Gmbh	Utilisation de dérivés d'acide 1-phényl-pyrazol-3-carboxylique à substitution en position 4 en tant qu'agents actifs contre le stress abiotique chez les végétaux
MX344109B (es)	2011-10-25	2016-12-05	Janssen Pharmaceutica Nv	Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico.
EP2819675A4 (fr) *	2012-02-27	2015-07-22	Essentialis Inc	Sels d'ouvreurs des canaux potassiques atp et leurs utilisations
CA2994924A1 (fr) *	2015-08-06	2017-02-09	Ube Industries, Ltd.	Derive de guanidine substitue
WO2017057695A1 (fr) *	2015-09-30	2017-04-06	東レ株式会社	Dérivé de diphénylpyrazol et son utilisation à des fins médicales
EP3872068A1 (fr) *	2015-12-16	2021-09-01	Nippon Soda Co., Ltd.	Composé de type arylazole et agent de lutte contre les organismes nuisibles
US10344002B2 (en)	2016-09-26	2019-07-09	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
CN108017584B (zh) *	2017-06-20	2021-03-23	南开大学	A3腺苷受体的小分子拮抗剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2104931B1 (fr) *	1970-09-08	1975-01-10	Ferlux
CA2121391A1 (fr) *	1993-04-28	1994-10-29	Atsuyuki Kojima	Derives d'indoloylguanidine
IL109570A0 (en) *	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US5852046A (en)	1993-08-03	1998-12-22	Hoechst Aktiengesellschaft	Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
EP0639573A1 (fr) *	1993-08-03	1995-02-22	Hoechst Aktiengesellschaft	Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
DE4412334A1 (de) *	1994-04-11	1995-10-19	Hoechst Ag	Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2160600A1 (fr) *	1994-10-18	1996-04-19	Masahumi Kitano	Derives de l'indoloylguanidine
CA2195697A1 (fr)	1996-02-02	1997-08-03	Masahumi Kitano	Derives substitues de la guanidine, procede pour leur obtention et leurs utilisations pharmaceutiques
JPH09291076A (ja)	1996-04-24	1997-11-11	Sumitomo Pharmaceut Co Ltd	置換グアニジン誘導体およびその製法
AR009435A1 (es) *	1996-12-16	2000-04-12	Yamanouchi Pharma Co Ltd	Derivado de guanaidina n-[carbonil(heteroaril-substituida de 5 miembros)], un inhibidor del intercambiador de na+/h+ que comprende dicho derivado y usosen la fabricacion de medicamentos.
KR100449600B1 (ko) *	1998-02-27	2004-09-21	화이자 프로덕츠 인크.	허혈 치료용 ｎ-[(치환된 5원 디아자 이불포화 고리)카르보닐] 구아니딘 유도체

1999
- 1999-02-05 KR KR10-2000-7009529A patent/KR100449600B1/ko not_active IP Right Cessation
- 1999-02-05 US US09/367,731 patent/US6492401B1/en not_active Expired - Fee Related
- 1999-02-05 PT PT99901083T patent/PT1056729E/pt unknown
- 1999-02-05 CN CN99802628A patent/CN1289326A/zh active Pending
- 1999-02-05 CA CA002321642A patent/CA2321642A1/fr not_active Abandoned
- 1999-02-05 ID IDW20001633A patent/ID25505A/id unknown
- 1999-02-05 YU YU46200A patent/YU46200A/sh unknown
- 1999-02-05 AT AT99901083T patent/ATE286034T1/de not_active IP Right Cessation
- 1999-02-05 ES ES99901083T patent/ES2237080T3/es not_active Expired - Lifetime
- 1999-02-05 KR KR10-2003-7012300A patent/KR20030083004A/ko not_active Application Discontinuation
- 1999-02-05 KR KR10-2002-7017553A patent/KR100407903B1/ko not_active IP Right Cessation
- 1999-02-05 IL IL13658899A patent/IL136588A0/xx unknown
- 1999-02-05 SI SI9930743T patent/SI1056729T1/xx unknown
- 1999-02-05 WO PCT/IB1999/000206 patent/WO1999043663A1/fr not_active Application Discontinuation
- 1999-02-05 DK DK99901083T patent/DK1056729T3/da active
- 1999-02-05 EA EA200000789A patent/EA003603B1/ru not_active IP Right Cessation
- 1999-02-05 AU AU20706/99A patent/AU739403B2/en not_active Ceased
- 1999-02-05 NZ NZ504769A patent/NZ504769A/en unknown
- 1999-02-05 KR KR10-2003-7009644A patent/KR20030078886A/ko not_active Application Discontinuation
- 1999-02-05 BR BR9908332-9A patent/BR9908332A/pt not_active IP Right Cessation
- 1999-02-05 PL PL99342444A patent/PL342444A1/xx not_active Application Discontinuation
- 1999-02-05 JP JP2000533420A patent/JP2002504546A/ja active Pending
- 1999-02-05 HU HU0204418A patent/HUP0204418A3/hu not_active Application Discontinuation
- 1999-02-05 EP EP04008203A patent/EP1454902A1/fr not_active Withdrawn
- 1999-02-05 TR TR2000/02480T patent/TR200002480T2/xx unknown
- 1999-02-05 SK SK1234-2000A patent/SK12342000A3/sk unknown
- 1999-02-05 EP EP99901083A patent/EP1056729B1/fr not_active Expired - Lifetime
- 1999-02-05 DE DE69922930T patent/DE69922930T2/de not_active Expired - Fee Related
- 1999-02-22 GT GT199900022A patent/GT199900022A/es unknown
- 1999-02-22 TW TW088102574A patent/TWI226329B/zh active
- 1999-02-23 PE PE1999000156A patent/PE20000334A1/es not_active Application Discontinuation
- 1999-02-24 PA PA19998468401A patent/PA8468401A1/es unknown
- 1999-02-24 DZ DZ990032A patent/DZ2729A1/fr active
- 1999-02-24 TN TNTNSN99028A patent/TNSN99028A1/fr unknown
- 1999-02-25 AR ARP990100791A patent/AR015526A1/es unknown
- 1999-02-25 AP APAP/P/1999/001478A patent/AP9901478A0/en unknown
- 1999-02-26 ZA ZA9901578A patent/ZA991578B/xx unknown
- 1999-03-01 CO CO99012526A patent/CO4980897A1/es unknown
2000
- 2000-06-27 IS IS5548A patent/IS5548A/is unknown
- 2000-08-18 OA OA1200000223A patent/OA11450A/en unknown
- 2000-08-22 NO NO20004192A patent/NO20004192L/no not_active Application Discontinuation
- 2000-08-24 HR HR20000550A patent/HRP20000550A2/hr not_active Application Discontinuation
- 2000-09-27 BG BG104803A patent/BG104803A/bg unknown
2001
- 2001-08-29 HR HR20010666A patent/HRP20010666A2/hr not_active Application Discontinuation
2002
- 2002-12-09 US US10/315,369 patent/US6974813B2/en not_active Expired - Fee Related
2004
- 2004-08-27 JP JP2004248129A patent/JP2005041879A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US20030149043A1 (en)	2003-08-07
US6974813B2 (en)	2005-12-13
DE69922930D1 (de)	2005-02-03
AU2070699A (en)	1999-09-15
EA200000789A1 (ru)	2001-02-26
ATE286034T1 (de)	2005-01-15
AP9901478A0 (en)	1999-03-31
WO1999043663A1 (fr)	1999-09-02
HRP20010666A2 (en)	2001-10-31
AU739403B2 (en)	2001-10-11
EP1454902A1 (fr)	2004-09-08
BR9908332A (pt)	2000-11-07
OA11450A (en)	2003-12-04
HRP20000550A2 (en)	2001-02-28
HUP0204418A3 (en)	2003-10-28
KR100449600B1 (ko)	2004-09-21
CN1289326A (zh)	2001-03-28
BG104803A (bg)	2001-05-31
KR20010041397A (ko)	2001-05-15
GT199900022A (es)	2000-08-15
DE69922930T2 (de)	2005-12-29
ID25505A (id)	2000-10-05
HUP0204418A2 (hu)	2003-04-28
NO20004192D0 (no)	2000-08-22
ES2237080T3 (es)	2005-07-16
ZA991578B (en)	2000-08-28
YU46200A (sh)	2003-02-28
EP1056729B1 (fr)	2004-12-29
NZ504769A (en)	2005-04-29
NO20004192L (no)	2000-08-22
PA8468401A1 (es)	2000-09-29
PT1056729E (pt)	2005-04-29
AR015526A1 (es)	2001-05-02
SI1056729T1 (en)	2005-04-30
KR20030009548A (ko)	2003-01-29
JP2002504546A (ja)	2002-02-12
EA003603B1 (ru)	2003-06-26
PE20000334A1 (es)	2000-05-13
CO4980897A1 (es)	2000-11-27
TWI226329B (en)	2005-01-11
KR20030078886A (ko)	2003-10-08
IS5548A (is)	2000-06-27
KR100407903B1 (ko)	2003-12-01
TR200002480T2 (tr)	2000-12-21
TNSN99028A1 (fr)	2005-11-10
EP1056729A1 (fr)	2000-12-06
PL342444A1 (en)	2001-06-04
JP2005041879A (ja)	2005-02-17
US6492401B1 (en)	2002-12-10
DK1056729T3 (da)	2005-04-11
IL136588A0 (en)	2001-06-14
CA2321642A1 (fr)	1999-09-02
SK12342000A3 (sk)	2001-03-12
KR20030083004A (ko)	2003-10-23

Publication	Publication Date	Title
DZ2729A1 (fr)	2005-03-01	Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant.
DZ3052A1 (fr)	2004-03-27	Composés nouveaux inhibiteurs de métalloprotéases,procédé pour leur préparation et compositions pha rmaceutiques les contenant.
CY2537B1 (fr)	2006-06-28	Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2753A1 (fr)	2005-09-15	Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr)	2004-03-15	Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2465A1 (fr)	2003-01-18	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
DZ2360A1 (fr)	2002-12-28	Dérivés de pyrazole procédé pour leur préparation et compositions les contenant
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3016A1 (fr)	2004-03-20	Composés nouveaux inhibiteurs de réabsorption de monoamines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr)	2003-12-15	4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2440A1 (fr)	2003-01-11	Atropisomères de 3-aryl-4(3h)-quinazolinones procédé pour leur préparation et compositions les contenant.
DZ2758A1 (fr)	2003-09-15	Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3038A1 (fr)	2004-03-27	Modulateurs nouveaux des récepteurs de glucocorticoïdes, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2745A1 (fr)	2003-09-08	BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2581A1 (fr)	2003-02-22	Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2394A1 (fr)	2003-06-04	Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26611A1 (fr)	2004-12-20	Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant